Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer.

Combined androgen deprivation therapy (ADT) and radiotherapy (RT) improves outcomes for intermediate and high-risk prostate cancer. Treatment intensification with abiraterone acetate/prednisone (AAP) provides additional benefit for high-risk disease. We previously reported 3-year outcomes of a single-arm prospective multicenter trial (AbiRT trial) of 33 patients with unfavorable intermediate risk (UIR) and favorable high risk (FHR) prostate cancer undergoing short course, combination therapy with ADT, AAP, and RT. Here we report the final analysis demonstrating a high rate of testosterone recovery (97%) and excellent biochemical progression-free survival (97%) at 5 years. These data support comparative prospective studies of shorter, more potent ADT courses in favorable high-risk prostate cancer.

Duke Scholars

Author Daniel James George Medicine, Medical Oncology

Author Ryan Everett Fecteau Radiation Oncology

Author Susan Halabi Biostatistics & Bioinformatics, Division of Biostatistics

Author Lauren Howard  

Author Tian Zhang Medicine, Medical Oncology

Author W. Robert Lee Radiation Oncology

Author Michael Roger Harrison Medicine, Medical Oncology

Author Andrew John Armstrong Medicine, Medical Oncology